INTELLIGENT BIO SOLUTIONS INC
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
INBS$2.25-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three Months Ended September 30, | |||
|---|---|---|---|
| 2024 · 2023 | |||
| Cash Flows from Operating Activities | |||
| Net loss | $(2,694,799) | $(2,432,424) | |
| Adjustments to reconcile net loss to cash used in operating activities: | |||
| Depreciation and amortization | 241,622 | 247,598 | |
| Amortization on right-of-use assets | 61,489 | 59,962 | |
| Provision for inventory obsolescence | - | 67,851 | |
| Share-based compensation | 202,045 | - | |
| Non-cash refund of R&D expenditure claims | (86,037) | (33,523) | |
| Fair value gain on revaluation of holdback Series C preferred stock | - | (131,250) | |
| Non-cash other operating activities | (33,170) | 104,485 | |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (148,874) | (273,649) | |
| Inventories | 38,748 | (53,035) | |
| Grant receivable / deferred grant income | - | (97,128) | |
| Research and development tax incentive receivable | (123,002) | (60,830) | |
| Deferred charges | (127,586) | - | |
| Other current assets | 101,379 | 139,486 | |
| Accounts and other payables | 221,335 | 1,215,964 | |
| Other long-term liabilities | 6,116 | 2,830 | |
| Operating lease liabilities | (46,482) | (68,170) | |
| Net cash used in operating activities | (2,387,216) | (1,311,833) | |
| Cash flows from Financing Activities | |||
| Proceeds from issuance of common stock, net of costs | 34,511 | - | |
| Proceeds from exercise of warrants | 7,939 | - | |
| Net cash provided by financing activities | 42,450 | - | |
| Effect of foreign exchange rates on cash and cash equivalents | 30,099 | (39,010) | |
| Net decrease in cash and cash equivalents | (2,314,667) | (1,350,843) | |
| Cash and cash equivalents, beginning of period | 6,304,098 | 1,537,244 | |
| Cash and cash equivalents, end of the period | $3,989,431 | $186,401 | |
| Non-cash investing and financing activities | |||
| Equity issuance costs in accounts payable and accrued expenses | $127,586 | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.